euro-biotechnology-genomics-congress-2018-posters

3 / 3

Page 47
Note:
N o v e m b e r 2 6 - 2 7 , 2 0 1 8 | M a d r i d , S p a i n
&
&
BIOTECHNOLOGY
Euro Congress on
GENOMICS AND MOLECULAR BIOLOGY
International Conference on
CANCER SCIENCE AND THERAPY
Global Congress on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Euro Biotechnology 2018 & Genomics Congress 2018 & Cancer Congress 2018 Journal of RNA and Genomics | ISSN: 2591-7781 | Volume 14
Valery Gmiro et al., J RNA Genomics 2018, Volume 14
COMPARISON OF ANTIPARKINCON
ACTIVITY OF THE N-DECYLTROPINE (IEM-
1556) AND LEVODOPA IN RATS WITH
ROTENONE-INDUCED PARKINSONISM
Valery Gmiro and S E Serdyuk
Institute for Experimental Medicine, Russia
Rotenone-induced parkinsonism in rats is a common animal model of par-
kinsonism for the study of the anti-Parkinsonian action of new substanc-
es. N-decyltropine (IEM-1556) when administered orally in a dose of 10 mg/
kg significantly exceeds the anti-Parkinsonian activity of levodopa in a dose
of 20 mg/kg, since 3 times more than levodopa reduces the number of rats
with severe oligokinesia, and in contrast to levodopa completely eliminate
severe catalepsy in rats with rotenone-induced parkinsonism. IEM-1556 is a
safer agent than levodopa, since it eliminates the lethality of rats throughout
the experiment, whereas levodopa increases the lethality of rats by the end
of the experiment. Preliminary anesthesia of the gastric mucosa by 1% lido-
caine almost completely eliminates the antiparkinsonian activity of IEM-1556
in a dose of 10 mg/kg and does not affect the anti-Parkinsonian activity of
levodopa in a dose of 20 mg/kg. Consequently, stimulation of gastric, prob-
ably vagal afferents underlies the antiparkinsonian action of IEM-1556 in a
dose of 10 mg/kg, but not levodopa. Based on the results of the conducted
experiments, IEM-1556 can be proposed as a potential alternate for levodopa
in Parkinsonism patients resistant to levodopa.
Valery Gmiro is the leading Researcher of Institute of
Experimental Medicine (Russia). He has published more
than 150 papers in reputed journals. The main scientific
interest concerns the Chemistry and Pharmacology of bi-
ologically active compounds. He is the USSR State Prize
Winner for the investigations in the field of Physiology
of Synaptic Transmission. During the last years, he has
been working on the problem of the creation of adapto-
genic drugs acting through activation of afferent nerves.
These drugs were shown to be effective tools to study
the mechanisms of transmission of afferent signals and
may be of interest in clinical usage.
BIOGRAPHY